Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4AMQZ)

• Drug Name: Crofelemer Drug Info
• Synonyms: Fulyzaq (TN)

Indication

Disease Entry	ICD 11	Status	REF
HIV-associated diarrhoea	1A2Z	Approved	[1]

• Cross-matching ID:
  PubChem CID: 17397714
  TTD Drug ID: DM4AMQZ
  VARIDT Drug ID: DR01112

Molecule-Related Drug Atlas

Drug(s) Targeting Calcium-dependent chloride channel anoctamin (ANO)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Benzbromarone	DMC3YUA	Gout	FA25	Approved	[3]
NPPB	DMFIWAN	Discovery agent	N.A.	Investigative	[4]
DIDS	DMKSQUB	Discovery agent	N.A.	Investigative	[4]
9-anthroic acid	DMGCVT2	Discovery agent	N.A.	Investigative	[4]
SITS	DMCMIUG	Discovery agent	N.A.	Investigative	[4]
DCDPC	DMG9BFR	Discovery agent	N.A.	Investigative	[4]
tannic acid	DM52WGH	Discovery agent	N.A.	Investigative	[4]
Ins(3,4,5,6)P4	DMAQU71	Discovery agent	N.A.	Investigative	[4]

Drug(s) Targeting cAMP-dependent chloride channel (CFTR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ivacaftor	DMZC1HS	Cystic fibrosis	CA25	Approved	[5]
Tezacaftor and ivacaftor	DMY62FC	Acute lung injury	NB32.3	Approved	[6]
VX-661	DMJBXO3	Cystic fibrosis	CA25	Phase 3	[7]
ABBV-2222	DM4ZLTY	Cystic fibrosis	CA25	Phase 2	[8]
GLPG-1837	DMOCRYB	Cystic fibrosis	CA25	Phase 2	[8]
iOWH032	DM5TMYC	Diarrhea	ME05.1	Phase 2	[9]
Lumacaftor	DMCLWDJ	Cystic fibrosis	CA25	Phase 2	[10]
QBW251	DMQ5APT	Chronic obstructive pulmonary disease	CA22	Phase 2	[11]
ABBV-3067	DMB01L5	Cystic fibrosis	CA25	Phase 1	[8]
ABBV-2737	DMU6K37	Cystic fibrosis	CA25	Phase 1	[8]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Calcium-dependent chloride channel anoctamin (ANO)	TTOJI4S	ANO1_HUMAN	Modulator	[2]
cAMP-dependent chloride channel (CFTR)	TTRLZHP	CFTR_HUMAN	Modulator	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7453).
• [2] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [3] Anoctamin Channels in Human Myometrium: A Novel Target for Tocolysis.Reprod Sci. 2018 Nov;25(11):1589-1600.
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 708).
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [6] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [7] CFTR Modulators for the Treatment of Cystic Fibrosis. P T. 2014 Jul;39(7):500-11.
• [8] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [9] Developing novel antisecretory drugs to treat infectious diarrhea. Future Med Chem. 2011 Aug;3(10):1317-25.
• [10] A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med. 2014 Jul;2(7):527-38.
• [11] Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251). J Cyst Fibros. 2021 Mar;20(2):250-256.